Product Image

Contributor Information

  • Institute University of Birmingham

Tool Details

  • Tool name: Anti-CD21 [BU32]
  • Alternate names: Complement Component 3d Receptor 2; Epstein-Barr Virus Receptor 2; Complement C3d Receptor; EBV Receptor; C3DR; CD21 Antigen; CVID7; SLEB9; CD21; Cr2; CR
  • Clone: BU32
  • Tool type: Antibodies
  • Tool sub-type: Primary Antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: WB ; FACS ; IHC ; IF
  • Strain: Balb/c
  • Description: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and associates with CD19, CD81 and Leu13 to form a large signal-transduction complex involved in B-cell activation. By inducing release of proinflammatory cytokines and upregulating expression of molecules involved in antigen presentation, CR2 modulates critical monocyte functions that may be relevant to allergic and inflammatory disorders.
  • Immunogen: Myeloma cell line Rob
  • Isotype: IgG1
  • Research area: Cell signaling and signal transduction; Immunology
  • Myeloma used: NS0

  • For Research Use Only

Target Details

  • Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)
  • Target background: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and associates with CD19, CD81 and Leu13 to form a large signal-transduction complex involved in B-cell activation. By inducing release of proinflammatory cytokines and upregulating expression of molecules involved in antigen presentation, CR2 modulates critical monocyte functions that may be relevant to allergic and inflammatory disorders.

Application Details

  • Application: WB ; FACS ; IHC ; IF

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-CD3 [C363.29B]

#155234
Product Image

Anti-Delta Np73 [Delta Np73-2.1]

#160742
Product Image

Anti-TOM34 [TOM34-1.1]

#160756

References

  • •  Knapp, W. et al. eds. 1989. Leucocyte Typing IV Oxford University Press. ISBN-13: 978-0192618672
  • •  Leucocyte Typing III 1987. ISBN-13: 978-0192615527
  • •  Leucocyte Typing V 1995. ISBN-13: 978-0192623768
  • •  Leucocyte Typing VI 1998. Garland Publishing NY. ISBN-13: 978-0815327455
  • •  Ling, NR., Brown, B., Immunobiology (1992) 185(2-4) pp403-14
  • •  Jackson et al. 2020. BMC Genet. 21(1):101. PMID: 32907542.
  • •  Herishanu et al. 2013. J Immunol. 190(2):784-93. PMID: 23241880.
  • •  Masilamani et al. 2004. Rheumatology (Oxford). 43(2):186-90. PMID: 12867574.
  • •  Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis.
  • •  Aubry et al. 1992. Nature. 358(6386):505-7. PMID: 1386409.
  • •  CD21 is a ligand for CD23 and regulates IgE production.